Health Technology Assessment: Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
Key data
Project team
Maria Carlander, Prof. Dr. Philipp Egli, Prof. Dr. Andreas Gerber-Grote, Cécile Grobet, Flurina Meier, Maxim Sharakin, Linda Vinci, Prof. Dr. Simon Wieser
Project status
completed, 01/2020 - 10/2021
Institute/Centre
Winterthur Institute of Health Economics (WIG); School of Health Sciences; Institute of Enterprise Law (IUR)
Funding partner
Bundesamt für Gesundheit BAG / Sektion Health Technology Assessment (HTA)
Project budget
165'000 CHF
